| 2020 |
Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body J-J, Minisola S. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Bone. January 2020;130:115113. |
0 |
0 |
| 2021 |
Diacinti D, Pisani D, Cipriani C, Celli M, Zambrano A, Diacinti D, Kripa E, Iannacone A, Colangelo L, Nieddu L, Pepe J, Minisola S. Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate. Bone. February 2021;143:115608. |
0 |
0 |
| 2023 |
De Martino V, Pepe J, Biamonte F, Colangelo L, Di Giuseppe L, Nieddu L, Occhiuto M, Minisola S, Cipriani C. Impairment in muscle strength and its determinants in primary hyperparathyroidism: a study in postmenopausal women. Bone. January 2023;166:116604. |
0 |
0 |
| 2021 |
Minisola S, Brandi ML. Phosphate metabolism. Calcif Tiss Int. January 2021;108(1):1-2. |
0 |
0 |
| 2022 |
Pepe J, Rossi M, Battafarano G, Vernocchi P, Conte F, Marzano V, Mariani E, Mortera SL, Cipriani C, Rana I, Buonuomo PS, Bartuli A, De Martino V, Pelle S, Pascucci L, Toniolo RM, Putignani L, Minisola S, Fattore AD. Characterization of extracellular vesicles in osteoporotic patients compared to osteopenic and healthy controls. J Bone Miner Res. November 2022;37(11):2186-2200. |
0 |
0 |
| 2022 |
Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE-H, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML; International Workshop on Primary Hyperparathyroidism. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop. J Bone Miner Res. November 2022;37(11):2293-2314. |
3 |
0 |
| 2022 |
Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2315-2329. |
5 |
1 |
| 2022 |
Fuleihan GE-H, Chakhtoura M, Cipriani C, Eastell R, Karonova T, Liu J-M, Minisola S, Mithal A, Moreira CA, Peacock M, Schini M, Silva B, Walker M, El Zein O, Marcocci C. Classical and nonclassical manifestations of primary hyperparathyroidism. J Bone Miner Res. November 2022;37(11):2330-2350. |
3 |
2 |
| 2018 |
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. January 20, 2018;391(10117):230-240. |
29 |
24 |
| 2015 |
Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwiński E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int. December 2015;26(12):2773-2783. |
22 |
15 |
| 2020 |
Colangelo L, Pepe J, Nieddu L, Sonato C, Scillitani A, Diacinti D, Angelozzi M, Cipriani C, Minisola S. Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia. Osteoporos Int. July 2020;31(7):1383-1387. |
1 |
1 |
| 2020 |
Body J-J, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Möricke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. October 2020;31(10):1935-1942. |
0 |
0 |